Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$64.73K$64.73Kderived+326.3% vs Q4 2013 Net Income-$1.02M-$1.02MderivedN/M vs Q4 2013 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$31,357+245.0% Operating Incomederived-$957,634N/M Operating Cash Flowderived-$302,200N/M Margins · derivedGross margin48.4%−11.4 pt vs Q4 2013
Operating margin-1479.5%+2908.3 pt vs Q4 2013
Net margin-1575.6%+2139.7 pt vs Q4 2013
ended Dec 31, 2014 · filed Mar 31, 2015 · 90 d after period end